Signaturefd LLC reduced its position in Bristol-Myers Squibb Company (NYSE:BMY) by 3.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,130 shares of the biopharmaceutical company’s stock after selling 527 shares during the period. Signaturefd LLC’s holdings in Bristol-Myers Squibb were worth $714,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in BMY. Blue Chip Partners Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the period. Keel Point LLC boosted its stake in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 18 shares during the period. Staley Capital Advisers Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock worth $379,000 after buying an additional 24 shares during the period. Shayne & CO. LLC boosted its stake in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 27 shares during the period. Finally, Founders Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 29 shares during the period. 69.79% of the stock is owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Company (BMY) traded up 0.25% during midday trading on Friday, hitting $56.73. 4,060,530 shares of the stock traded hands. The firm has a market cap of $93.03 billion, a PE ratio of 20.72 and a beta of 1.17. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $60.86. The stock has a 50-day moving average of $55.80 and a 200 day moving average of $54.64.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the firm posted $0.69 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. Equities analysts forecast that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.
TRADEMARK VIOLATION NOTICE: “Signaturefd LLC Has $714,000 Stake in Bristol-Myers Squibb Company (NYSE:BMY)” was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.thestockobserver.com/2017/08/12/signaturefd-llc-has-714000-stake-in-bristol-myers-squibb-company-nysebmy.html.
BMY has been the subject of several research analyst reports. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday. BMO Capital Markets reaffirmed an “underperform” rating and set a $47.00 target price (down from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. Leerink Swann cut their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research note on Friday, July 28th. Finally, Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 target price for the company in a research note on Thursday. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $62.12.
In other news, Director Theodore R. Samuels II acquired 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.